Post by Sia/LBG

Many pharmaceutical organizations still rely on disconnected spreadsheets to evaluate product costs.    The challenge isn't that the models are wrong.    It's that critical development, manufacturing, and investment decisions are often being made using fragmented data, inconsistent assumptions, and limited visibility into cost drivers.    What if cost modeling became a strategic asset rather than a periodic exercise?    By digitizing Cost of Goods (COGs) modeling and integrating it into the broader product development process, organizations can:  - Evaluate multiple development pathways earlier  - Compare manufacturing scenarios in real time  - Improve cross-functional collaboration  - Standardize assumptions and data management  - Accelerate decision-making across R&D, CMC, Operations, and Finance The real value isn't simply calculating costs more efficiently.    It's enabling teams to make better decisions earlier—when there is still time to influence outcomes.    As product development becomes increasingly complex, the organizations that connect scientific expertise, cost intelligence, and digital tools will be best positioned to optimize development timelines, improve commercial readiness, and drive long-term value.    Want to know more? Contact our experts in the comments. #DrugDevelopment #CostModeling #COGS